Cargando…

Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy

We developed an immunochromatography-based assay for detecting antibodies against recombinant α-galactosidase A proteins in serum. The evaluation of 29 serum samples from Fabry patients, who had received enzyme replacement therapy with agalsidase alpha and/or agalsidase beta, was performed by means...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakano, Sachie, Tsukimura, Takahiro, Togawa, Tadayasu, Ohashi, Toya, Kobayashi, Masahisa, Takayama, Katsuyoshi, Kobayashi, Yukuharu, Abiko, Hiroshi, Satou, Masatsugu, Nakahata, Tohru, Warnock, David G., Sakuraba, Hitoshi, Shibasaki, Futoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470989/ https://www.ncbi.nlm.nih.gov/pubmed/26083343 http://dx.doi.org/10.1371/journal.pone.0128351

Ejemplares similares

Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease
por: Tsukimura, Takahiro, et al.
Publicado: (2014)

Development of a Highly Sensitive Immuno-PCR Assay for the Measurement of α-Galactosidase A Protein Levels in Serum and Plasma
por: Nakano, Sachie, et al.
Publicado: (2013)

Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?
por: Tsukimura, Takahiro, et al.
Publicado: (2021)

Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease
por: Shiga, Tomoko, et al.
Publicado: (2021)

Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy
por: Tsukimura, Takahiro, et al.
Publicado: (2020)

Monitoring of anti-drug antibodies and disease-specific biomarkers in three patients from a Japanese Fabry family treated with enzyme replacement therapy
por: Kubota, Takao, et al.
Publicado: (2022)

Cell Transplantation Combined with Recombinant Collagen Peptides for the Treatment of Fabry Disease
por: Kami, Daisuke, et al.
Publicado: (2020)

Genetically Modified Cell Transplantation Through Macroencapsulated Spheroids with Scaffolds to Treat Fabry Disease
por: Kami, Daisuke, et al.
Publicado: (2021)

Fabry disease in a Japanese population-molecular and biochemical characteristics
por: Sakuraba, Hitoshi, et al.
Publicado: (2018)

Massive accumulation of globotriaosylceramide in various tissues from a Fabry patient with a high antibody titer against alpha-galactosidase A after 6 years of enzyme replacement therapy
por: Hongo, Kenichi, et al.
Publicado: (2020)

Clinical and biochemical investigation of male patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues; a pitfall in diagnosis of Fabry disease
por: Sakuraba, Hitoshi, et al.
Publicado: (2015)

Development and usefulness of an immunochromatographic device to detect antibodies for rapid diagnosis of human gnathostomiasis
por: Janwan, Penchom, et al.
Publicado: (2016)

Screening of Fabry disease in patients with chronic kidney disease in Japan
por: Nagata, Akiko, et al.
Publicado: (2021)

Erratum to: Screening of Fabry disease in patients with chronic kidney disease in Japan
por: Nagata, Akiko, et al.
Publicado: (2021)

Effectiveness of immunosuppressive therapy for nephrotic syndrome in a patient with late-onset Fabry disease: a case report and literature review
por: Fujisawa, Hironobu, et al.
Publicado: (2019)

Surface plasmon resonance analysis of complex formation of therapeutic recombinant lysosomal enzymes with domain 9 of human cation-independent mannose 6-phosphate receptor
por: Kanzaki, Minori, et al.
Publicado: (2020)

Frequency of de novo mutations in Japanese patients with Fabry disease
por: Kobayashi, Masahisa, et al.
Publicado: (2014)

In Vivo Delivery of Therapeutic Molecules by Transplantation of Genome-Edited Induced Pluripotent Stem Cells
por: Nakajima, Ittetsu, et al.
Publicado: (2023)

Fluorescent Immunochromatography for Rapid and Sensitive Typing of Seasonal Influenza Viruses
por: Sakurai, Akira, et al.
Publicado: (2015)

Optimizing human α-galactosidase for treatment of Fabry disease
por: Hallows, William C., et al.
Publicado: (2023)

Characteristics of the Electrocardiogram in Japanese Fabry Patients Under Long-Term Enzyme Replacement Therapy
por: Morimoto, Satoshi, et al.
Publicado: (2021)

The role of native T1 values on the evaluation of cardiac manifestation in Japanese Fabry disease patients
por: Anan, Ikuko, et al.
Publicado: (2022)

Broad-Spectrum Detection of H5 Subtype Influenza A Viruses with a New Fluorescent Immunochromatography System
por: Sakurai, Akira, et al.
Publicado: (2013)

Adipocytes participate in storage in α-galactosidase deficiency (Fabry disease)
por: Hůlková, Helena, et al.
Publicado: (2010)

Development of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies
por: Endo, Fumiko, et al.
Publicado: (2017)

Receptor-Mediated Endocytosis of α-Galactosidase A in Human Podocytes in Fabry Disease
por: Prabakaran, Thaneas, et al.
Publicado: (2011)

A Novel α-Galactosidase A Splicing Mutation Predisposes to Fabry Disease
por: Li, Ping, et al.
Publicado: (2019)

Rats deficient in α-galactosidase A develop ocular manifestations of Fabry disease
por: Miller, James J., et al.
Publicado: (2019)

Lyso-GM2 Ganglioside: A Possible Biomarker of Tay-Sachs Disease and Sandhoff Disease
por: Kodama, Takashi, et al.
Publicado: (2011)

Globotriaosylsphingosine Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

A Novel Frameshift Mutation of Galactosidase-alpha in Fabry Disease Restricted to Dermatologic Manifestations
por: Kim, Dae Hun, et al.
Publicado: (2013)

Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease
por: Hofmann, Lukas, et al.
Publicado: (2017)

Coincidental finding of Fabry’s disease in a patient with IgA nephropathy
por: Kakita, Tomoko, et al.
Publicado: (2010)

Late onset variants in Fabry disease: Results in high risk population screenings in Argentina
por: Serebrinsky, G., et al.
Publicado: (2015)

Long-Term Effect of Enzyme Replacement Therapy with Fabry Disease
por: Komori, Manabu, et al.
Publicado: (2013)

Correction: Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
por: Lenders, Malte, et al.
Publicado: (2016)

Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease
por: Modrego, Andrea, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nqgbpmnr1f9o1fm31bro0jpn1c